奥司他韦联合蒲地蓝消炎口服液治疗儿童流行性感冒的临床疗效及其药物分析

Clinical efficacy of oseltamivir combined with Pudilan anti-inflammatory oral liquid in the treatment of childhood influenza and its drug analysis

目的探讨儿童流行性感冒临床开展治疗以奥司他韦+蒲地蓝消炎口服液的疗效及药物价值.方法研究样本筛选时间在2022年1月-2022年12月期间,以入院展开流行性感冒治疗患儿为参考,共选取182例,基于红蓝球法进行组别划分,组名设定为参照组、研究组,每组各有患儿91例,前者行奥司他韦治疗,后者行奥司他韦+蒲地蓝消炎口服液治疗.对比组间疗效(治愈、显效、有效、无效)、症状缓解时间(鼻塞、咳嗽、咽部红肿)、血清炎性因子(IL-6、CRP、INF-γ)等指标.结果研究组治疗有效率为97.80%,高于参照组的85.71%(P<0.05);症状缓解时间统计发现研究组的各项时间值均更短(P<0.05);研究组的血清炎性因子各指标均较低(P<0.05);不良反应发生率也是研究组较低(P<0.05).结论儿童流行性感冒临床开展治疗时以奥司他韦、蒲地蓝消炎口服液联合用药表现出显著的效果,对患儿临床相关症状改善具有积极影响,且用药安全性相对较高,相比单一用药效果更佳,值得推广.

Objective To explore the efficacy and value of oseltamivir plus Pudilan Xiaoyan oral liquid in the treatment of childhood influenza.Methods The screening time was 2022.1-2022.12.A total of 182 children with influenza treatment were divided into two groups according to the red basketball method,the former was treated with oseltamivir,while the latter was treated with oseltamivir plus Pudilan antiphlogistic oral solution.The therapeutic effect(cure,obvious effect,effective and ineffective),the time of symptom relief(nasal obstruction,cough,pharyngeal swelling)and serum inflammatory factors(IL-6,CRP,INF-γ)were compared between the two groups.Results 97.80%of the patients in the study group were higher than those in the control group 85.71%(P<0.05),and the time of symptom relief was shorter in the study group(P<0.05).The serum inflammatory factors were lower in the study group(P<0.05),and the adverse reactions were lower in the study group(P<0.05).Conclusion The combination of oseltamivir and Pudilan xiaoyan oral liquid is of significant value in the treatment of children with influenza and has a positive effect on the improvement of clinical symptoms,and the drug safety is relatively high,compared with single drug effect is better,it is worth promoting.